TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01696604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2849466
Description: GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2849466
Description: GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2849466
Description: GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2849466
Description: GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2849466
Description: GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be available.
Study: NCT00218218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: 42 mg transdermal nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21 mg transdermal nicotine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Study: NCT04593199

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gamified Smartphone App
Description: The primary objective was to determine the acceptability and satisfaction of the Draco app among children. Secondary objective was to evaluate if the Draco app could improve physical activity levels (steps, and moderate-to-vigorous physical activity) and intrinsic motivation for physical activity in children. The gamified smartphone app, Draco, is a virtual pet simulator where you care for a pet by exercising, walking, and answering healthy lifestyle questions.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Physical activity tracking app
Description: Participants were asked to use the Fitbit app to track and sync their daily physical activity.
Study: NCT01086358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptan
Description: Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treximet 85Mg-500Mg Tablet
Description: Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
Study: NCT04174404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICory-Circumcision
Description: The ICory-Circumcision is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children. The ICory-Circumcision programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery while the healthcare professional would receive face-to-face training on how to use the BuddyCare dashboard.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.
Study: NCT00578292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2 Day -5 through Day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: Per institutional guidelines Days -5 through -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg Days -5 through -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA
Description: 10 mg/kg x 5 Days -5 through -2
Study: NCT00033267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study: NCT03391739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19 cells
Description: CART-19 cells treat
Study: NCT02977962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy
Description: This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
Study: NCT02270372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONT-10, Varlilumab combination
Description: ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27.
Study: NCT00921518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)
Description: 0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
Study: NCT05376033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: root canal filling with Ceraseal sealer
Description: root canal filling with Ceraseal sealer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: root canal filling with Ceraseal sealer
Description: root canal filling with Ceraseal sealer

Intervention type: OTHER
Group type: OTHER
Intervention: root canal filling with Ceraseal sealer
Description: root canal filling with Ceraseal sealer
Study: NCT02105961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile 0.9percent sodium chloride solution
Study: NCT03018262

Intervention type: DEVICE
Intervention: TMS - sub-study 1
Description: TMS pulses will be applied to the motor hotspot of the surround muscle to identify the TMS-evoked potentials corresponding to motor surround inhibition (SI)

Intervention type: DEVICE
Intervention: TMS - sub-study 2
Description: TMS will be used to stimulate the motor cortex and an inhibitory region of the inferior parietal lobe

Intervention type: DEVICE
Intervention: TMS - sub-study 3
Description: TMS pulses will be delivered to the primary motor cortex at rest, at the onset of the motor task, or during the motor task
Study: NCT01347411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Treatment with CPAP
Study: NCT01185665

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulator

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-TENS
Description: TENS without electrical output, from the outside not different from a normal TENS
Study: NCT03367078

Intervention type: DEVICE
Intervention: Anodal tDCS
Description: Anodal tDCS, on L-DLPFC area, is started 2 weeks after admission to the sABI Operative Unit with: one session per day (in the morning), possibly for 5 consecutive days per week (from Monday to Friday), for 2 consecutive weeks. Each tDCS session lasts 20 minutes. Current intensity is 1 mA during the first week, 2 mA in the second week

Intervention type: OTHER
Intervention: Usual care
Description: Usual care of DOC patients

Intervention type: OTHER
Intervention: Usual care
Description: Usual care of DOC patients
Study: NCT01013103

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin, high vs low dose
Description: In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin vs Placebo
Description: In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
Study: NCT03733886

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)
Description: Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)
Description: Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold
Study: NCT04195893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Contact Lens
Study: NCT02873117

Intervention type: OTHER
Intervention: Prostate biopsy, prostatectomy or prostate resection
Description: Collection of prostate examination

Intervention type: OTHER
Intervention: Prostate biopsy, prostatectomy or prostate resection
Description: Collection of prostate examination
Study: NCT04229407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: MRI eligibility evaluation Dietary supplement drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise) for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin B
Description: MRI eligibility evaluation vitamin B drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise)for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
Study: NCT00085735

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Field Radiation Therapy
Description: Undergo smaller volume boost (involved-field radiation therapy)
Study: NCT03633539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-incision Laparoscopic Surgery
Description: Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laparoscopic Surgery
Description: Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
Study: NCT00085735

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Field Radiation Therapy
Description: Undergo smaller volume boost (involved-field radiation therapy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Field Radiation Therapy
Description: Undergo smaller volume boost (involved-field radiation therapy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00710541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilators designed for non invasive ventilation
Description: Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
Study: NCT00746135

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device Implantation
Description: RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device Implantation
Description: RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device Implantation
Description: RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
Study: NCT04456309

Intervention type: OTHER
Intervention: No intervention,
Description: pure observational study

Intervention type: OTHER
Intervention: No intervention,
Description: pure observational study
Study: NCT01802073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Study: NCT04075734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Your Health: Self-Management + Peer Mentoring
Description: The online educational component consists of 5 self-management educational modules:~(1) Understanding Your Survivorship Care Plan; (2) Managing Your Healthcare; (3) Family and Significant Other Involvement in Your Healthcare; (4) Emotions about Your Health and Follow-Up Care; (5) Staying Healthy.~Participants will be matched with a peer mentor and complete a total of six calls. The first call is to build a rapport and identify the participant's self-management strengths, weaknesses, and goals. The next five calls align with the topic of each module, which the mentee is expected to complete prior to their scheduled call.
Study: NCT04113213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Prescription (LRx)
Description: Lifestyle prescription, based on the UK WP10 medicinal prescription form. Includes advice and guidance regarding physical activity, diet, smoking and alcohol consumption.
Study: NCT04009811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suersen and membraneous obturators evaluation
Description: The patient will wear one month each obturator prothesis (Suersen and membraneous obturators). The order of evaluation will be randomized in two arms.~Half of patient will first wear one month the membranous obturator then one month the Suersen, the other half of patient will first wear one month the Suersen obturator and one month the membranous obturator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suersen and membraneous obturators evaluation
Description: The patient will wear one month each obturator prothesis (Suersen and membraneous obturators). The order of evaluation will be randomized in two arms.~Half of patient will first wear one month the membranous obturator then one month the Suersen, the other half of patient will first wear one month the Suersen obturator and one month the membranous obturator.
Study: NCT00085735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00338871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: home exercise
Study: NCT00397917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid: 4 mg versus 0.4 mg per day
Description: Folic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid: 4 mg versus 0.4 mg per day
Description: Folic acid
Study: NCT01384149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external slt
Description: Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard slt
Description: Nd:YAG LASER SLT gonioscopic laser treatment
Study: NCT02428283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 1 μg/kg was injected before skin incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
Study: NCT02989428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early parathyroidectomy group (EPTX-group)
Description: Participants will undergo parathyroidectomy as soon as possible
Study: NCT04303039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-671
Description: ABP-671 Tablet 1.0 mg
Study: NCT01905280

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-resorbable membrane
Description: The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix
Description: The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
Study: NCT02751502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: m2 Bimanual Arm Trainer (BAT)
Description: Patients in the device group will be asked to train specific movements repeatedly with the device for 45 minutes five days a week for 6 weeks and compliance will be monitored through training logs and remotely
Study: NCT02520232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of aerobic and strength exercises
Description: Combination of aerobic and strength exercises
Study: NCT01697618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
Study: NCT02520232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching and balance exercise program
Description: Stretching and balance exercise program
Study: NCT03937180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended care
Description: An interactive e-learning programme delivered through a secured web-based platform for patients and general practitioners (GPs), blended with face-to-face contacts between the involved GP and patient.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: General practitioners offering usual care are expected to follow the Belgian guidelines as described in the most recent online version of Anxiety, stress and sleeping problems A toolbox for general practitioners. or Sleeping pills and sedatives. How to assist your patients in the search for other solutions? which are both available in French and Dutch.
Study: NCT03499028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JointCOACH
Description: Patients randomized to this group will utilize JointCOACH to communicate with their surgical team, receive information
Study: NCT02868008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microsurgical resection of brain AVMs
Description: fMRI guided microsurgical resection of brain AVMs